Cargando…

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer

It remains controversial whether papillary thyroid cancer (PTC) patients with low- to intermediate-risk disease should receive radioactive iodine (RAI) after total thyroidectomy (TT). We aim to identify those who might benefit from RAI treatment in PTC patients with cervical nodal metastasis after T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Hengqiang, Gong, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402902/ https://www.ncbi.nlm.nih.gov/pubmed/36034423 http://dx.doi.org/10.3389/fendo.2022.960682

Ejemplares similares

Association between iodine nutrition and cervical lymph node metastasis of papillary thyroid microcarcinoma
por: Zhao, Hengqiang, et al.
Publicado: (2023)

The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer
por: Wang, Xiaofei, et al.
Publicado: (2020)

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer
por: Liu, Lina, et al.
Publicado: (2022)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Extent of Surgery and the Prognosis of Unilateral Papillary Thyroid Microcarcinoma
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
por: Cao, Jingjia, et al.
Publicado: (2022)

Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome
por: Lukovic, Jelena, et al.
Publicado: (2021)

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis
por: Zhao, Min, et al.
Publicado: (2022)

Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
por: Creach, Kimberly M., et al.
Publicado: (2012)

Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial
por: Jammah, Anwar A., et al.
Publicado: (2021)

The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER
por: Tang, Jianing, et al.
Publicado: (2018)

Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer
por: Lee, Chang-Hee, et al.
Publicado: (2018)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer
por: Bouvet, Clément, et al.
Publicado: (2019)

Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score–matched analysis
por: Guo, Honghao, et al.
Publicado: (2023)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis
por: Zhang, Xueqi, et al.
Publicado: (2022)

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
por: Qiu, Zhong-Ling, et al.
Publicado: (2020)

Prognostic significance of inflammatory markers LMR, PLR, MPV, FIB in intermediate-and high-risk papillary thyroid carcinoma
por: Li, Canxiao, et al.
Publicado: (2022)

Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma
por: Ma, Teng, et al.
Publicado: (2023)

Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer
por: Zhou, Ruo-Yun, et al.
Publicado: (2023)

Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine
por: Adamska, Agnieszka, et al.
Publicado: (2021)

Responses to the First Radioactive Iodine Treatment After Targeted Therapy for Aggressive Papillary Thyroid Cancers
por: Soe, Myat Han, et al.
Publicado: (2021)

“Adjuvant Radioactive iodine 133 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience”
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2015)

Radioactive Iodine Following Total Thyroidectomy Is Comparable to Lobectomy in Low/Intermediate-Risk Differentiated Thyroid Carcinoma: A Meta-Analysis
por: Altedlawi Albalawi, Ibrahim A, et al.
Publicado: (2020)

Prelaryngeal and/or pretracheal lymph node metastasis could help to identify papillary thyroid carcinoma with intermediate risk from unilateral lobe cT1-2N0 papillary thyroid carcinoma
por: Wang, Bin, et al.
Publicado: (2023)

BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer
por: Han, Sang-Ah, et al.
Publicado: (2014)

Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study
por: Chai, Jinyan, et al.
Publicado: (2022)

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
por: Súss, Shirlei Kugler Aiçar, et al.
Publicado: (2018)

The Iodine Rush: Over- or Under-Iodination Risk in the Prophylactic Use of Iodine for Thyroid Blocking in the Event of a Nuclear Disaster
por: Calcaterra, Valeria, et al.
Publicado: (2022)

Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
por: Chung, Jae Hoon
Publicado: (2013)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
por: Li, Wanting, et al.
Publicado: (2023)

The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis
por: Mirghani, Hyder, et al.
Publicado: (2021)

The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study
por: Dou, Yi, et al.
Publicado: (2021)

Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy
por: Bojarsky, Mya, et al.
Publicado: (2023)

The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodine—A cohort study
por: Luo, Hongxiu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kes960ddgpdvrg9sj9h9a0sf4l